Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 15/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.55 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749438 | 1.00 | PIK3CB (0.55) | PIK3CBPIK3CGPIK3CDPIK3CACKS1B | |
| SCHEMBL1750563 | 0.89 | PIK3CB (0.70) | PIK3CBPIK3CGPIK3CDPIK3CA | |
| SCHEMBL4056572 | 0.87 | PIK3CB (0.57) | PIK3CBPIK3CGPIK3CDPIK3CACSNK1D | |
| SCHEMBL1749641 | 0.78 | BTK (0.41) | CKS1BSKP1SKP2CSNK1D | |
| SCHEMBL1749640 | 0.78 | BTK (0.41) | CKS1BSKP1SKP2CSNK1D | |
| SCHEMBL4375798 | 0.78 | BTK (0.39) | CKS1BSKP1SKP2CSNK1D | |
| SCHEMBL1749660 | 0.76 | PIK3CA (0.66) | PIK3CBPIK3CGPIK3CDPIK3CA | |
| SCHEMBL300841 | 0.74 | PIK3CB (0.80) | PIK3CBPIK3CGPIK3CDPIK3CA | |
| SCHEMBL301214 | 0.74 | PIK3CB (0.80) | PIK3CBPIK3CGPIK3CDPIK3CA | |
| SCHEMBL300966 | 0.73 | PIK3CB (0.76) | PIK3CBPIK3CGPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | PIK3CB 267/4885PIK3CG 821/4885PIK3CD 649/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | PIK3CB 267/4885PIK3CG 780/4885PIK3CD 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.